Walvax Biotech Clarifies Recent Provincial Price Adjustments Are Isolated Incidents

Gelonghui, June 23 | An investor asked Walvax on the interactive platform: According to publicly listed information, the price of the company’s Group A and Group C meningococcal conjugate vaccine in Jiangsu Province has increased from approximately RMB 90 to RMB 198, and the ACYW135 quadrivalent meningococcal polysaccharide vaccine has increased from approximately RMB 130 to RMB 146. Is this an official price adjustment by the company? Does it constitute a nationwide price correction?

Walvax responded that, since the beginning of this year, the prices of its Group A and Group C meningococcal polysaccharide conjugate vaccine and its ACYW135 group meningococcal polysaccharide vaccine in the domestic market have remained generally stable. The recent adjustments to the winning bid prices in certain provinces are isolated cases; the adjusted prices will align with the overall domestic market pricing. For specific details, please refer to the public announcements issued by the relevant provincial authorities. This adjustment will not affect prices in other provinces.